[Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
8.4% of the isolated Pseudomonas aeruginosa strains were resistant against imipenem in this study. 3.7% of them became resistant as a result of the antibiotic therapy. In some patients on intensive care units, the resistance of Pseudomonas aeruginosa against imipenem emerged within a few days. In two of these cases a simultaneous loss of activity of the other pseudomonas-beta-lactams was observed.
D015377:Cilastatin; D003521:Cyclopropanes / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D015378:Imipenem; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013845:Thienamycins / Q000627:therapeutic use*
D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem
Resistenzentwicklung unter Imipenem-Therapie bei Pseudomonas aeruginosa.